Discover
APLS
Apellis Pharmaceuticals, Inc.
41.03
14 x 41.02
1 x 41.05
bid
ask
+
0.00
0.00%
8 @ 04:00 PM
41.06 +0.03 (0.07%)
| Ytd | 63.34% | |
| 1y | 150.79% |
41.03
day range
41.03
16.61
52 week range
41.14
| Open | 41.05 | Prev Close | 41.03 | Low | 41.03 | High | 41.03 | Mkt Cap | 5.25B |
| Vol | 28.64M | Avg Vol | 6.37M | EPS | 1.07 | P/E | 38.35 | Forward P/E | -103.09 |
| Beta | -0.25 | Short Ratio | 1.15 | Inst. Own | 110.43% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 33.60 | 200-d Avg | 26.15 | 1yr Est | 40.92 |
| Income Statement | |||
| Total Revenue | 268.30M | ||
| Revenues (USD) | 268.30M | ||
| Cost of Revenue | 40.55M | ||
| Gross Profit | 227.75M | ||
| Operating Expenses | 201.28M | ||
| Research and Development Expense | 76.96M | ||
| Selling, General and Administrative Expense | 124.32M | ||
| Operating Income | 26.47M | ||
| Interest Expense | 10.32M | ||
| Income Tax Expense | 496.00K | ||
| Net Income | 18.66M | ||
| Net Income Common Stock | 18.66M | ||
| Net Income Common Stock (USD) | 18.66M | ||
| Consolidated Income | 18.66M | ||
| Earnings per Basic Share | 0.15 | ||
| Earnings per Basic Share (USD) | 0.15 | ||
| Earnings per Diluted Share | 0.15 | ||
| Earning Before Interest & Taxes (EBIT) | 29.47M | ||
| Earning Before Interest & Taxes (USD) | 29.47M | ||
| Weighted Average Shares | 127.68M | ||
| Weighted Average Shares Diluted | 131.42M | ||
| Balance Sheet | |||
| Cash and Equivalents | 406.73M | ||
| Cash and Equivalents (USD) | 406.73M | ||
| Trade and Non-Trade Receivables | 440.30M | ||
| Current Assets | 1.03B | ||
| Property, Plant & Equipment Net | 20.36M | ||
| Total Assets | 1.08B | ||
| Debt Current | 100.71M | ||
| Total Debt | 475.76M | ||
| Current Liabilities | 283.45M | ||
| Debt Non-Current | 375.05M | ||
| Total Liabilities | 667.61M | ||
| Accumulated Retained Earnings (Deficit) | -2.99B | ||
| Accumulated Other Comprehensive Income | -2.41M | ||
| Shareholders Equity | 414.92M | ||
| Shareholders Equity (USD) | 414.92M | ||
| Assets Non-Current | 54.51M | ||
| Total Debt (USD) | 475.76M | ||
| Inventory | 159.90M | ||
| Liabilities Non-Current | 384.16M | ||
| Trade and Non-Trade Payables | 49.05M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 291.00K | ||
| Net Cash Flow from Financing | 64.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -61.03M | ||
| Issuance (Purchase) of Equity Shares | 86.00K | ||
| Net Cash Flow from Operations | -60.97M | ||
| Effect of Exchange Rate Changes on Cash | -131.00K | ||
| Share Based Compensation | 25.17M | ||